Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination regimen used ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...

Losing: A film that does not recover the investment but loses less than 50% of it Flop: Film that loses 50% or more of its investment * denotes that the film is still running in theatres. Explore how ...

Thanks to robot mops, you no longer need to exert any elbow grease to have a shiny floor. Like robot vacuums, you can now find a dizzying variety of robot mops with a range of features and prices. At ...